Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Grows By 61.9%

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 3,400 shares, an increase of 61.9% from the July 31st total of 2,100 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 57,100 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Evoke Pharma in a research report on Saturday, August 24th. They issued a “sell” rating on the stock.

Evoke Pharma Price Performance

NASDAQ EVOK traded down $0.02 during mid-day trading on Friday, reaching $4.29. The stock had a trading volume of 19,956 shares, compared to its average volume of 24,847. The stock has a market cap of $36.88 million, a PE ratio of -2.34 and a beta of 0.38. Evoke Pharma has a 1 year low of $3.75 and a 1 year high of $18.60. The company has a fifty day moving average price of $5.75 and a 200 day moving average price of $6.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The business had revenue of $2.55 million for the quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.